Avantor Performance Materials Expands Presence in India

Avantor Performance Materials recently announced it has opened a new pharmaceuticals formulation applications laboratory at the RanQ Remedies facility, an established excipient developer and manufacturer based in Sinnar Nashik, India. Following Avantor’s recent acquisition of RFCL Limited in India, the opening of this new laboratory shows a strong commitment to growth and expansion in the region.

The new lab, which strengthens a strategic development and manufacturing agreement between Avantor and RanQ, will be used to characterize excipients; perform functional testing; develop and characterize drug formulations; and support customer applications and product implementation.

In addition to an applications laboratory, Avantor has completed construction of a pilot plant onsite at the RanQ facility. The pilot plant will be used to develop and scale-up additional performance excipients to extend Avantor’s J.T.Baker PanExcea product line. The PanExcea line includes performance excipients that combine filler, binder, and disintigrant to provide increased excipient functionality for immediate-release and orally disintegrating tablet applications.

“Our partnership with Avantor will allow us to advance our goal of becoming an internationally known, high-quality excipient manufacturer,” said Managing Director of RanQ, Sameer Ranadive. “We look forward to developing a broad range of performance excipients to assist customers in the global pharmaceutical industry.”

RanQ has extensive process development and manufacturing capabilities and expertise. The company is known for developing premixed and other application-focused pharmaceutical excipients that result in a homogenous mix and co-processed excipients that eliminate the need for wet granulation production stages.

“With our proven excipient innovation experience, beaker-to-bulk packaging flexibility, and Q7A quality systems, RanQ will serve as a strategic pharmaceutical partner in the region,” added Avantor Executive Vice President of Pharmaceuticals Paul Smaltz.

“RanQ’s capabilities will help us increase the commercialization speed of Avantor’s line of J.T.Baker PanExcea performance excipients,” said Mr. Smaltz. “By working with RanQ on customer applications, we expect that this alliance will facilitate a rapid introduction of additional novel, high-performance excipients to the global pharmaceutical market.”

“This base of applications support complements our other activities in India,” said Avantor Executive Vice President of Southeast Asia Sushil Mehta. “Our expanded presence will enable us to quickly develop more unique and effective solutions that help customers increase their speed to market.”

“Avantor is a global leader continuing to build upon a legacy of innovation by expanding into new global regions,” said Mr. Smaltz. “Our new applications laboratory will allow Avantor to provide additional value to customers who are developing high-volume manufacturing operations in the Southeast Asian region by conveniently testing and developing drug formulations on site.”

Avantor is continuing to expand in the Southeast Asia region. The company recently acquired RFCL Limited, a leader in laboratory reagents and consumables as well as products for medical diagnostics. Avantor purchased RFCL because of its current presence in the laboratory and pharmaceutical markets in fast-growing Indian market.